GOVX vs. PHAS, VRPX, MBIO, REVB, EVOK, PHIO, BCEL, HILS, ARDS, and ENSC
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include PhaseBio Pharmaceuticals (PHAS), Virpax Pharmaceuticals (VRPX), Mustang Bio (MBIO), Revelation Biosciences (REVB), Evoke Pharma (EVOK), Phio Pharmaceuticals (PHIO), Atreca (BCEL), Hillstream BioPharma (HILS), Aridis Pharmaceuticals (ARDS), and Ensysce Biosciences (ENSC). These companies are all part of the "pharmaceutical preparations" industry.
GeoVax Labs (NASDAQ:GOVX) and PhaseBio Pharmaceuticals (NASDAQ:PHAS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations.
In the previous week, GeoVax Labs' average media sentiment score of 0.00 equaled PhaseBio Pharmaceuticals'average media sentiment score.
GeoVax Labs presently has a consensus price target of $120.00, indicating a potential upside of 8,350.70%.
GeoVax Labs has a net margin of 0.00% compared to PhaseBio Pharmaceuticals' net margin of -12,572.13%. PhaseBio Pharmaceuticals' return on equity of 0.00% beat GeoVax Labs' return on equity.
6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 49.0% of PhaseBio Pharmaceuticals shares are owned by institutional investors. 4.0% of GeoVax Labs shares are owned by insiders. Comparatively, 9.9% of PhaseBio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
GeoVax Labs has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, PhaseBio Pharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.
GeoVax Labs has higher earnings, but lower revenue than PhaseBio Pharmaceuticals. GeoVax Labs is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
PhaseBio Pharmaceuticals received 107 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 91.67% of users gave GeoVax Labs an outperform vote while only 61.78% of users gave PhaseBio Pharmaceuticals an outperform vote.
Summary
PhaseBio Pharmaceuticals beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
